Antonia Wierzbicki, Waters Corporation - Qepler Summits And Conferences

Antonia Wierzbicki

Principal Pharma Market Development Manager EMEA
Waters Corporation
Waters offers a comprehensive range of analytical system solutions, software, and services for scientists. Liquid Chromatography. Mass Spectrometry.

Antonia Wierzbicki is a marketing manager at Waters working in EMEA. Antonia has BSc in Pharmaceutical Science and a MSc in Cancer Pharmacology. Following several years working as an analytical chemist in drug development roles within both academic labs and contract research organizations, Antonia has more recently spent time working with analytical chemists to provide solutions using cutting edge technologies to meet their needs and requirements, with a specific interest in ultra-sensitive quantitation of small molecules. Antonia is based in Cambridge UK and keen to connect with like-minded scientists in the field.

“I have always been fascinated by science, specifically pharmacology and toxicology. I love seeing how science has evolved during my career and the innovation in technology that has driven this field to grow so quickly to benefit patients. It is great to see with the recent regulations and work around genotoxic impurities that the pharmaceutical industry continues to refine its practices for the benefit of patient safety. I hope in future to also see a similar change to reduce the environmental impact of drug discovery and pharmaceutical manufacturing to greater enhance the health and wellbeing of patients”

Related Sessions:

3rd Annual Genotoxic Impurities
in Pharmaceuticals Summit 2023

Genotoxic Impurities in Pharmaceuticals strategies & new methodologies: analysis, in silico & regulations.
  • 09 Mar 2023
  • Virtual,
  • Pharma
Day 1: Thursday, 09 March 2023
CASE STUDY: Technologies for Optimising Performance, Minimising Risk and preparing for the Future in Trace Impurity Quantification

Quantification of GTIs can be challenging particularly when considering the complex and diverse matrices, combined with ever changing and extremely low limits of quantification. Continuing with the theme of evaluating risk, I am going to expand this to considering the risk to analytical integrity, presenting the methodologies developed to quantify genotoxic impurities including nitrosamines and boronic acids. I’ll discuss a systematic approach to quantitative method development, some of the analytical issues that can arise, and share some of the latest waters technologies that are used for low level quantification of GTIs and explain how their inclusion in the analytical workflow can help mitigate predicted and unforeseen analytical errors and issues.

View Details